Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 10/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4349250 | 0.89 | F2R (0.62) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL4338978 | 0.88 | F2R (0.49) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346258 | 0.85 | F2R (0.52) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346249 | 0.83 | F2R (0.69) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4351865 | 0.82 | F2R (0.67) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346256 | 0.82 | F2R (0.67) | F2RMAOBBCHEMAOAACHE | |
| Trifluoroacetic Acid SCHEMBL4340439 | 0.81 | F2R (0.62) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL6849519 | 0.81 | F2R (0.66) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4340591 | 0.81 | F2R (0.66) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL5585203 | 0.80 | F2R (0.65) | F2RMAOBBCHEMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | H1-2, H1-3, H1-4 | F2R 2393/4885MAOB 2255/4885BCHE 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.